| __timestamp | Halozyme Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 612613000000 |
| Thursday, January 1, 2015 | 40028000 | 650773000000 |
| Friday, January 1, 2016 | 45853000 | 619061000000 |
| Sunday, January 1, 2017 | 53816000 | 628106000000 |
| Monday, January 1, 2018 | 60804000 | 717599000000 |
| Tuesday, January 1, 2019 | 77252000 | 964737000000 |
| Wednesday, January 1, 2020 | 45736000 | 875663000000 |
| Friday, January 1, 2021 | 50323000 | 886361000000 |
| Saturday, January 1, 2022 | 143526000 | 997309000000 |
| Sunday, January 1, 2023 | 149182000 | 1053819000000 |
| Monday, January 1, 2024 | 154335000 | 1053819000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Halozyme Therapeutics, Inc. from 2014 to 2023. Over this period, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, marking a 72% rise from 2014. In contrast, Halozyme's expenses, while significantly lower, have also seen a notable increase, reaching around 149 million dollars in 2023, a fourfold increase from 2014. This disparity highlights the scale and operational differences between the two companies. Notably, the data for 2024 is incomplete, reflecting the dynamic nature of financial reporting. As the pharmaceutical landscape continues to shift, these insights provide a window into the strategic priorities of these industry giants.
Who Optimizes SG&A Costs Better? Sanofi or Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.